Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer
Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that failed to respond to docetaxel and cabazitaxel. He subsequently received a third line of chemotherapy with cyclophosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.
Target Audience
This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe current treatment options for metastatic prostate cancer
- Discuss the potential for major response to cyclophosphamide and prednisone in recurrent castrate-resistant prostate cancer (CRPC)
Nicolas Batty, MD, FACP, FASCP
Department of Medicine
Roswell Park Cancer Center
Buffalo, New York
Naveen Yarlagadda, MD
Department of Medicine
Roswell Park Cancer Center
Buffalo, New York
Roberto Pili, MD
Department of Medicine
Roswell Park Cancer Center
Buffalo, New York
Available Credit
- 1.00 Participation
- 1.00 Nurse
- 1.00 Physician
Price
Required Hardware/software
To access this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for article and certificate viewing/printing